Ixabepilone (Ixempra) was approved on 10/16/07 for treatment of metastatic breast cancer. The specific approval is: (1) Ixebepilone in combination with capecitabine (Xeloda) for treatment of metastatic or locally advanced breast cancer patients who have become resistant to anthracycline (such as Adriamycin) and taxane therapy (such as Taxotere or Taxol), or for patients who are resistant to taxane therapy, in whom further anthracycline therapy is contraindicated, and (2) Ixebepilone as monotherapy for treatment of metastatic or locally advanced breast cancer patients whose tumors are resistant to anthracyclines, taxanes, and capecitabine.
CORT was part of the multicenter study that established the efficacy of ixabepilone, and our physicians and nurses are experienced in management of this treatment. CORT applauds the FDA decision to approve this drug, which should expand the treatment choices for these patients who have limited other treatment options. For more information about treatment with ixabepilone, contact the CORT office at 972-566-5588 (Dallas), or at 972-981-4012 (Plano). Information about CORT and the innovative treatments and studies offered can be found at our website: www.CORTPA.com.
Center for Oncology Research & Treatment--Dallas, TX 